SWP
BBIO icon

Stratos Wealth Partners’s BridgeBio Pharma BBIO Stock Holding History

Stratos Wealth Partners’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$493K Sell
6,640
-100
-1% -$7.25K 0.01% 1071
2025
Q4 		$516K Hold
6,740
– – 0.01% 1034
2025
Q3 		$350K Buy
+6,740
New +$329K ﹤0.01% 1177

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Stratos Wealth Partners's BBIO Position: Q1 2026 in Review

Stratos Wealth Partners reduced its BridgeBio Pharma (BBIO) stake by 1.5% in Q1 2026, selling an estimated $7.25K and leaving 6,640 shares worth $493K. The position accounts for 0.01% of the portfolio, ranked #1071.

Stratos Wealth Partners first reported a position in BBIO in Q3 2025 and has held it in 3 quarters since. The position peaked at $516K in Q4 2025. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Stratos Wealth Partners held 6,640 shares of BridgeBio Pharma worth $493K as of Q1 2026.
  • Stratos Wealth Partners sold 100 BridgeBio Pharma shares in Q1 2026, an estimated $7.25K.
  • BridgeBio Pharma made up 0.01% of Stratos Wealth Partners's portfolio in Q1 2026, its #1071 holding.
  • Stratos Wealth Partners first reported a position in BridgeBio Pharma in Q3 2025 and has held it in 3 quarters since.
  • Stratos Wealth Partners's BridgeBio Pharma position peaked at $516K in Q4 2025.
  • 457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Stratos Wealth Partners's 13F filing for Q1 2026, filed 28 Apr 2026.